Publication | Closed Access
Low-dose Methotrexate for Vitiligo.
19
Citations
0
References
2017
Year
RheumatologyAutoimmune DiseaseClinical TherapeuticImmunodeficienciesPharmacologyImmunologyFolic Acid SupplementationClinical DermatologyCase SeriesAutoimmunityLow-dose MethotrexatePharmacotherapySkin PharmacologyDermatologyExperimental DermatologyImmunotherapyMedicineSignificant Skin Repigmentation
BACKGROUND: Treatment of vitiligo is aimed at repigmentation and often consists of multiple modalities, none of which are universally or rapidly successful. Extensive cases are most often treated with ultraviolet light therapy, which can be both costly and time-consuming. Though vitiligo is an autoimmune disease, there is no current data to support systemic immunosuppressive monotherapy. CASE SUMMARY: Here we present a case series of 3 patients with vitiligo treated for 11-16 months with low-dose methotrexate (12.5-25 mg per week) with folic acid supplementation with clinically significant skin repigmentation, with response within 6 months in one case. There were no severe adverse effects reported. CONCLUSION: These cases demonstrate an unexplored effective and steroid-sparing therapeutic alternative in patients with vitiligo for whom topical therapy has failed and phototherapy is cost-prohibitive or ineffective. <em>J Drugs Dermatol. 2017;16(7):705-706.</em> .